Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus

Huang, Qiulan; Huang, Yan-ting; Liu, Jianping

doi:10.1155/2021/9938658

Cited by 17 publications

(10 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the number of studies using MSCs for the treatment of T2DM is small, their findings support the safety of MSCs, with no severe adverse events observed during the course of these studies. 270 It was confirmed that MSC therapy potentially reduced fasting blood glucose and HbA1 C levels and increased C-peptide levels. However, these effects were short-term, and multiple doses were required to maintain the MSC effects.…”

Section: Endocrine Disorders Infertility/reproductive Function Recove...mentioning

confidence: 88%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

398

138

View full text Add to dashboard Cite

Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment.

show abstract

Section: Endocrine Disorders Infertility/reproductive Function Recove...mentioning

confidence: 88%

Stem cell-based therapy for human diseases

Hoang

Pham

Bach

et al. 2022

Sig Transduct Target Ther

398

138

View full text Add to dashboard Cite

show abstract

“…However, although MSCs migrate to the pancreas, the differentiation into IPCs is minimal, and it is not the explanation for the possible regenerative effects induced by cell therapy. On injured pancreatic islets, beneficial effects are consequent to the immunomodulatory, anti-inflammatory and anti-apoptotic actions of the molecules secreted by MSCs, which protect endogenous β-cells, stimulate their regeneration and proliferation and ameliorate insulin resistance, reversing hyperglycemia, the main determinant of DCM [ 102 ]. Regarding cardiac repair, MSCs have protective and regenerative effects in several types of cardiovascular diseases [ 103 ].…”

Section: Preclinical and Clinical Approaches To Msc In Diabetes-induced Cardiac Complicationsmentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Gonçalves

Vasques

et al. 2022

Cells

View full text Add to dashboard Cite

The incidence and prevalence of diabetes mellitus (DM) are increasing worldwide, and the resulting cardiac complications are the leading cause of death. Among these complications is diabetes-induced cardiomyopathy (DCM), which is the consequence of a pro-inflammatory condition, oxidative stress and fibrosis caused by hyperglycemia. Cardiac remodeling will lead to an imbalance in cell survival and death, which can promote cardiac dysfunction. Since the conventional treatment of DM generally does not address the prevention of cardiac remodeling, it is important to develop new alternatives for the treatment of cardiovascular complications induced by DM. Thus, therapy with mesenchymal stem cells has been shown to be a promising approach for the prevention of DCM because of their anti-apoptotic, anti-fibrotic and anti-inflammatory effects, which could improve cardiac function in patients with DM.

show abstract

“…Since 2014, WJ-MSCs has been tipped to become the new gold standard for MSC-based therapies [ 82 ]. There has been much consent towards Wharton’s jelly as an interesting source of cells for clinical application, and relevant for translation to the field of DM cell therapy [ 84 , 85 ]. The most recent significance of the WJ-MSC’s clinical effectiveness derived from clinical trials involving in severe inflammation-based diseases, such as severe acute respiratory distress syndrome (ARDS) [ 86 , 87 , 88 ] in the coronavirus disease 2019 (COVID-19) context [ 89 , 90 , 91 ].…”

Section: Perinatal Cellsmentioning

confidence: 99%

Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of Differentiation and Immunomodulation

Paris

Pizzuti

Marrazzo

et al. 2022

IJMS

View full text Add to dashboard Cite

Human term placenta and other postpartum-derived biological tissues are promising sources of perinatal cells with unique stem cell properties. Among the massive current research on stem cells, one medical focus on easily available stem cells is to exploit them in the design of immunotherapy protocols, in particular for the treatment of chronic non-curable human diseases. Type 1 diabetes is characterized by autoimmune destruction of pancreatic beta cells and perinatal cells can be harnessed both to generate insulin-producing cells for beta cell replenishment and to regulate autoimmune mechanisms via immunomodulation capacity. In this study, the strong points of cells derived from amniotic epithelial cells and from umbilical cord matrix are outlined and their potential for supporting cell therapy development. From a basic research and expert stem cell point of view, the aim of this review is to summarize information regarding the regenerative medicine field, as well as describe the state of the art on possible cell therapy approaches for diabetes.

show abstract

Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus

Cited by 17 publications

References 77 publications

Stem cell-based therapy for human diseases

Stem cell-based therapy for human diseases

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Perinatal Stem Cell Therapy to Treat Type 1 Diabetes Mellitus: A Never-Say-Die Story of Differentiation and Immunomodulation

Contact Info

Product

Resources

About